ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / IVF
BJDX (38) NXGL (28) ICCM (33) CODX (29) ⌘ Pro Terminal β†’

INVO Fertility Inc. (IVF) β€” RQD Stock Rating Cockpit

$1.83 -4.19% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.81

INVO Fertility Inc. (IVF) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $2.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IVF Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is IVF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, INVO Fertility Inc. (NASDAQ: IVF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.83 (-4.19% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, IVF ranks #615 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does IVF compare to BJDX and NXGL in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), IVF carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, BJDX (Bluejay Diagnostics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and NXGL (NexGel Inc) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M). Among the 5-stock peer group, IVF leads on earnings multiple (N/A) while IVF leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IVF?
β–Ό

Per IVF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001417926), INVO Fertility Inc. generated $6.8M in revenue (+4.3% YoY), $23.3M in net income, and -$7.1M in free cash flow against $20.2M in total assets and $744.7K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.81 (-0.94%)🧬 Disciplined Float (+0.16% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D+
Cash (4)Whales (3)SEC (10)Macro (11)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-10.4% Base Target
$103 Bull$2 Base$1 Bear
πŸ“¬ FREE IVF RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for IVF)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY IVF SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+11/20 pts (31% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 41.4 (NEUTRAL RANGE)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$2.36-7.2% Next Q
Q2 (-2Q)
40
Grade D$2.19+1.4% Next Q
Q3 (-1Q)
38
Grade E$2.22-17.6% Next Q
Current
35
Grade D-$1.83-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a IVF Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While IVF currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.18) and Max Pain ($1.92) forces dealer call-delta covering toward $102.98.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IVFβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œIVF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
41.430 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.83H: $98
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on IVF

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-35.0% ROIC with 96.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (35)

10/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like IVF
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IVF)

  • βœ“Walkthrough of IVF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
IVF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.79%β–Ό DESCENDING CHANNEL
2026-11-04O $1.91H $1.91L $1.83C $1.83VOL 55.4K
RES: $9.22SUP: $0.42SMA50: $3.18SMA200: $8.80
$91.12$66.57$42.02$17.47$-7.08RES $9.22SUP $0.42$1.832026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IVF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ IVF Butterfly Map β†’ + Track IVF β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IVF today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for IVF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IVF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IVF)

Health Care Rank #615 of 1015 βš”οΈ BJDX vs IVF Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (IVF vs. BJDX, NXGL, ICCM, CODX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, INVO Fertility Inc. (IVF) ranks #615 by composite RQD confidence (35/100, grade D-) and #990 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, IVF leads on earnings valuation at N/A trailing P/E, while IVF leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. BJDX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with IVF at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IVF ACTIVE
INVO Fertility Inc.
D- 35/100 β€” 96.0% -35.0% -4.19% $2.1M Benchmark Subject
BJDX
Bluejay Diagnostics Inc.
D- 38/100 β€” β€” -35.0% -4.74% $2.4M /bjdx-vs-ivf β†’
NXGL
NexGel Inc
E 28/100 β€” 39.5% -35.0% +7.98% $1.8M /nxgl-vs-ivf β†’
ICCM
IceCure Medical Ltd.
E 33/100 β€” 36.3% -35.0% -3.14% $2.9M /iccm-vs-ivf β†’
CODX
Co-Diagnostics Inc.
E 29/100 β€” 64.3% -35.0% -3.65% $3.1M /codx-vs-ivf β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001417926 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), INVO Fertility Inc. (IVF) reported GAAP revenue of $6.8M (+4.3% vs. FY2024 revenue of $6.6M , and +126.5% cumulative change since FY2023) , GAAP net income of $23.3M, operating cash flow of -$7.0M, and free cash flow of -$7.1M (-123.5% YoY). On the balance sheet, IVF closed FY2025 with $20.2M in total assets against $744.7K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.8M $23.3M -$7.0M -$7.1M $20.2M $744.7K
FY2024 (FY) 2024-12-31 $6.6M $9.1M -$3.0M -$3.2M $46.1M $1.1M
FY2023 (FY) 2023-12-31 $3.0M $8.0M -$4.8M -$4.8M β€” β€”

3. IVF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IVF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, INVO Fertility Inc. (NASDAQ: IVF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.83 (-4.19% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, IVF ranks #615 in composite RQD confidence.

How does IVF compare to BJDX and NXGL in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), IVF carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, BJDX (Bluejay Diagnostics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and NXGL (NexGel Inc) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M). Among the 5-stock peer group, IVF leads on earnings multiple (N/A) while IVF leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IVF?

Per IVF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001417926), INVO Fertility Inc. generated $6.8M in revenue (+4.3% YoY), $23.3M in net income, and -$7.1M in free cash flow against $20.2M in total assets and $744.7K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IVF trading relative to its 50-day, 200-day, and 52-week technical levels?

IVF last traded at $1.83 (-4.19% on volume of 55,383 shares), positioning the stock -42.45% below its 50-day simple moving average ($3.18) and -79.20% below its 200-day simple moving average ($8.80). Across its 52-week range of $0.54 to $98.08, IVF sits at the 1.3% percentile with a 14-day RSI of 41.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.60 to $2.06).

Direct Sub-Reports: IVF RQD Cockpit IVF 12M Forecast IVF Earnings & Move IVF Dividends & DRIP IVF Insiders & 13F IVF Whale Options IVF Profit Sankey IVF News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

IVF β€” INVO Fertility Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

INVO Fertility Inc. (IVF) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.83 (-4.19% 1D, market capitalization $2.1M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of 0.10x.

2. Business Model, Unit Margins & SEC Financial Trajectory

INVO Fertility Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry,. FY 2025 revenue was $6.8M against an operating loss of -$7.2M, indicating the company does not currently generate operating profit.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), INVO Fertility Inc. (IVF) reported $6.8M in annual revenue (up from $6.6M in FY2024, +4.3% YoY) and $23.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.0M revenue, $8.0M net income) through FY2025, IVF scaled operating cash flow to -$7.0M and free cash flow to -$7.1M, backed by $20.2M in total assets against $744.7K in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.54 – $98.08 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are β€” Investors should note that the sector and industry classification alone does not establish any specific supplier or customer relationships.

  • Key Question #1: Can IVF sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.8M and free cash flow of -$7.1M, how will capital allocation balance growth reinvestment against $744.7K in total debt?
  • Key Question #3: How sensitive is IVF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IVF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for INVO Fertility Inc. (IVF) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to IVF Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IVF Bull vs. Bear Conversation Board β€” What's Your Call at $1.83?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IVF 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IVF:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $2.33 (+22.0%)
πŸ“Œ Pinned Debate

Debt/Equity of 0.1 with a Piotroski F-Score of 5/9 indicates limited leverage and moderate financial health.

Picked up a starter position in IVF in my $100K Virtual Cash book at $1.91. Debt/Equity of 0.1 with a Piotroski F-Score of 5/9 indicates limited leverage and moderate financial health.. Trading inside a $0.54–$98.08 52-week range with 0.0% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

SectorRotator πŸ‚ BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (96.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.57 (-17.8%)
Spot @ $1.91

ROIC of -35% and a 0% FCF yield leave the cash engine unable to support value, with the stock at $0.54 near the bottom of its $0.54 - $

Here is the bear case nobody on the bull side wants to address on IVF: ROIC of -35% and a 0% FCF yield leave the cash engine unable to support value, with the stock at $0.54 near the bottom of its $0.54 - $106.4 range.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE